Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ: AMPH )

23.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 728
Open 23.56
Bid (Size) 22.94 (1)
Ask (Size) 25.00 (1)
Prev. Close 23.56
Today's Range 23.56 - 23.56
52wk Range 22.64 - 53.95
Shares Outstanding 48,081,433
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Reasons to Like AMPH and 1 to Stay Skeptical
What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
Via ACCESS Newswire

Performance

YTD
-35.20%
-35.20%
1 Month
-17.22%
-17.22%
3 Month
-34.81%
-34.81%
6 Month
-52.72%
-52.72%
1 Year
-42.41%
-42.41%

More News

Read More
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
Via ACCESS Newswire
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals.
Via Chartmill
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
Via ACCESS Newswire
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
Via ACCESS Newswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
Via Benzinga
Amphastar: Earnings Miss, Margins Drop
Via The Motley Fool
Topics Earnings
Exposures Financial
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Earnings Scheduled For February 27, 2025
Via Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Via StockStory
Top 2 Health Care Stocks That May Rocket Higher This Month
Via Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
Via ACCESS Newswire
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
NASDAQ:AMPH is an undervalued gem with solid fundamentals.
Via Chartmill
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Investors should take notice of NASDAQ:AMPH—it offers a great deal for the fundamentals it presents.
Via Chartmill
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
NASDAQ:AMPH is an undervalued gem with solid fundamentals.
Via Chartmill
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.